NIH-sponsored clinical trial of chikungunya vaccine opens

(NIH/National Institute of Allergy and Infectious Diseases) An experimental vaccine to protect against the mosquito-borne illness chikungunya is being tested in a Phase 2 trial sponsored by the National Institutes of Health. Results from an initial trial of the vaccine were reported in 2014. In that study, all 25 vaccine recipients developed robust immune responses and no safety concerns were noted. The new trial is will enroll 400 healthy adult volunteers aged 18 to 60 years old at six sites in the Caribbean.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news